Tweets
Work ability is impaired in the majority of axSpA patients as measured by the WAI score. 996 patients were included with a mean WAI score of 31.7. Overall, 28%/43% of patients were in poor/moderate work ability, were older, more often obese , had lower education level and… https://t.co/D7oFn31Of5 https://t.co/g79riND9AO
Links:
Dr. Antoni Chan @synovialjoints ( View Tweet )
1 year 7 months ago
Deep B cell depletion strategies for Drug resistant RA @RheumNow #EULAR2024
for those which dont want to use CAR-T cells / other options.
Maybe used in other diseases. https://t.co/joRhfWaiDs
Links:
Bella Mehta @bella_mehta ( View Tweet )
1 year 7 months ago
Is Izokibep the new kid on the block in PsA?
➡️ IL-17A inhibitor
➡️ Complete resolution of enthesitis at 16w
➡️ Overall good safety data
LBA0005 #EULAR2024 @RheumNow https://t.co/8htPOz9YCG
Links:
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 7 months ago
#EULAR2024 POS0326 Multicentre cohort in Italy (N=67) showed Benralizumab and Mepolizumab 300mg (EGPA dose) exhibited a significant steroid-sparing effect, with MEPO300 demonstrating superior drug survival. MEPO100 (eosinophilic asthma dose) was numerically inferior @RheumNow
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
EULAR
OP0041 (2024)
COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash @drpnash ( View Tweet )
1 year 7 months ago
Reassessment of the cut-off values for ASDAS disease activity states in a large, multinational cohort of axSpA patients resulted in cut-offs largely similar to the currently endorsed cut-offs of 1.3, 2.1 and 3.5. Cut-off values between ID and LDA and between LDA and HDA, however,… https://t.co/vECCsmTggW https://t.co/XU7BQBYBdQ
Links:
Dr. Antoni Chan @synovialjoints ( View Tweet )
1 year 7 months ago
EULAR
OP0092 (2024)
INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash @drpnash ( View Tweet )
1 year 7 months ago
#EULAR2024 highlight from Prof Pitzalis & team- synovial phosphoproteome analysis in late-stage RA identifies signalling pathways assoc with pathotype & response to RTX & TOC
Study highlights active signalling pathways assoc with pathotype & drug response
OP0218 @RheumNow https://t.co/RZMSgj9T6k
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 7 months ago
Spatial transcriptomics work highlighted at #EULAR2024 @RheumNow https://t.co/5NvX1PW2tA
Links:
Bella Mehta @bella_mehta ( View Tweet )
1 year 7 months ago
Basic Science highlights at #EULAR2024 @RheumNow https://t.co/gr3Mysp3f4
Bella Mehta @bella_mehta ( View Tweet )
1 year 7 months ago
New validated BASDAI cut offs. BASDAI values of <2, <4 and >6 are often applied as cut-offs between remission, low (LDA), high (HDA) and very high (VHDA) disease activity, respectively, although this remains unvalidated. The optimal BASDAI values against external criteria were… https://t.co/5cvWoddHaN https://t.co/oBwYmFsIga
Links:
Dr. Antoni Chan @synovialjoints ( View Tweet )
1 year 7 months ago
#EULAR2024 POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characterisation. Multicentre study in Korea showed protective effect on Serious Infection btw those treated vs not. Effect was seen in the first 3mths only @RheumNow https://t.co/dCzD21589S
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 year 7 months ago
